Skip to content Skip to footer
Subscribe Now

NEWS

Incyte Partners with Halozyme to Develop Subcutaneous INCA033989
Shots: Incyte has entered into a global collaboration & license agreement with Halozyme to evaluate additional SC formulations of INCA033989 for pts with mutCALR-expressing myeloproliferative neoplasms, using Halozyme's Enhanze tech As per the deal, Halozyme will receive an upfront payment, as well as milestone payments, plus royalties, with Incyte having an option to nominate up…
July 21, 2026
Personalis
Tempus AI to Acquire Personalis for ~$1.5B
Shots: Tempus AI has entered into a definitive agreement to acquire Personalis, expanding Tempus' capabilities in minimal residual disease (MRD) As per the deal, Personalis shareholders will receive $16.25 per share, valuing the company at an enterprise value of $1.5B, net of Tempus AI’s existing ownership interest; closing expected in late 2026 or early 2027…
July 21, 2026
Samsung Bioepis and Organon
Organon and Samsung Bioepis Expand Commercialisation Agreement to Broaden Biosimilar Access in Australia
Shots: Organon & Samsung Bioepis have expanded their development and commercialisation agreement to commercialise a new biosimilar in Australia As per the deal, Organon will receive exclusive commercial rights to the biosimilar in Australia while Samsung Bioepis will be responsible for full development, manufacturing & regulatory responsibilities The amended agreement expands their collaboration to 4…
July 20, 2026
Almirall Reports EMA Acceptance of Ebglyss Pediatric Filing for Atopic Dermatitis in Children Aged 6 Months and Older
Shots: The EMA has accepted a submission to extend marketing authorization of Ebglyss (lebrikizumab) to pts (6mos. to <18yrs., weighing <40kg) with mod. to sev. atopic dermatitis Application was supported by interim data from the pediatric clinical program, incl. the ADorable-1 evaluating Ebglyss in pts (6mos. to <18yrs.), & the ADorable-2 LTE study assessing safety…
July 20, 2026
GSK Reports EMA Submission Acceptance to Update Bexsero Label
Shots: The EMA has accepted a submission to update Bexsero’s label to incl. a single-dose booster for individuals (≥10yrs.) who were previously vaccinated with Bexsero Submission was backed by a P-IIIb study showing that a single Bexsero booster dose effectively enhanced immune responses in individuals (10–20yrs.) who completed primary vaccination series during infancy; full data…
July 20, 2026
Samsung Biologics to Acquire PolyPeptide for ~$1.8B
Shots: Samsung Biologics has launched an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide, expanding its capabilities beyond antibodies & ADCs to include peptide therapeutics As per the deal, PolyPeptide will receive CHF 44.31 (~$54.8) in cash per share, representing an implied equity value of ~CHF 1.46B (~$1.8B);…
July 20, 2026
Load more